Skip to search formSkip to main contentSkip to account menu

SB 1518

Known as: SB-1518, SB1518 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pacritinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Exposure-Response Analysis For Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis
Background Pacritinib (SB1518) is a novel oral JAK2-FLT3 inhibitor. To date, once-daily (QD) dosing of pacritinib has been… 
2012
2012
JAK2 inhibitors and their impact in myeloproliferative neoplasms
Abstract The BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera, and… 
2012
2012
nonaene ( SB 1578 ) , a Potent Inhibitor of Janus Kinase 2 / Fms-LikeTyrosine Kinase-3 ( JAK 2 / FLT 3 ) for the Treatment of Rheumatoid Arthritis
Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within… 
2011
2011
Abstract 3570: SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Janus kinase 2 (JAK2) and fms-related… 
2011
2011
Abstract 3564: Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Here we present the unique chemical… 
2010
2010
Abstract 2524: SB1518, a novel oral JAK2-FLT3 inhibitor, is efficacious in models of acute myeloid leukemia and primary leukemic cells from patients
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Introduction FLT3 and JAK2 are tyrosine kinases… 
Review
2010
Review
2010
FDA Pipeline Preview, November 2010 (Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol extended-release oral analgesic, AVP-21D9, 1% tenofovir vaginal gel, AFM 13, hGH-CTP…
Recent FDA action (through, October 2010) related to Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol… 
2009
2009
Pharmacodynamic (PD) Biomarker Assay Validation for SB1518, a Novel Oral JAK2 Inhibitor in Phase 1 Clinical Trials for Advanced Leukemias, Myeloproliferative Diseases and Lymphoma.
Abstract 1888 Poster Board I-911 Introduction: Abnormalities in JAK2 and FLT3 kinases are reported in various hematological… 
2009
2009
The Effects of SB1518, a Novel Oral JAK2 Inhibitor, On Ex Vivo Expanded PV Erythroid Progenitors Correlate with Clinical Observations.
Abstract 2913 Poster Board II-889 Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) in which the… 
2007
2007
SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.
JAK2 is the most common mutated gene in bcr-abl-negative chronic myeloproliferative disorders (MPDs) making it an attractive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)